Petricoin and Liotta get a new machine with all the trimmings, gratis:
>>FREMONT, Calif., April 28 /PRNewswire-FirstCall/ -- Ciphergen Diagnostics, a division of Ciphergen Biosystems, Inc. (Nasdaq: CIPH - News), announced today that it has executed a material transfer agreement with the NCI Clinical Proteomics Reference Laboratory (CPRL) which allows CPRL to evaluate the new ProteinChip® System, Series 4000 and ProteinChip arrays and associated bioinformatics suites. The CPRL was created by the NCI to explore a variety of proteomics platforms which may have potential use to detect protein patterns indicative of various cancer states.
Under the terms of the agreement, Ciphergen will provide instrumentation, biochip arrays and software that the NCI CPRL will use to study biomarker patterns indicative of ovarian cancer. The NCI CPRL will test archived ovarian cancer samples on assays it has constructed on Ciphergen's proteomics platform.
"We are excited to be working with the NCI CPRL on this important project," said Gail S. Page, President of Ciphergen's Diagnostics Division. "This relationship brings together Ciphergen's expertise in rapidly translating biomarker discoveries into assays with the CPRL's extensive experience in clinical assay development and diagnostic test validation."
At the annual meeting of the Association for Laboratory Automation in February 2005, the NCI CPRL presented results of a study of ovarian cancer sera with total inter-day precision of 6-12% based on the use of the ProteinChip System, PBSIIc which is the predecessor system to the Series 4000.<<
snip
Cheers, Tuck |
